VX-509 (Decernotinib), an Oral Selective JAK-3 Inhibitor, in Combination With Methotrexate in Patients With Rheumatoid Arthritis. [electronic resource]
Producer: 20160503Description: 46-55 p. digitalISSN:- 2326-5205
- Administration, Oral
- Adult
- Aged
- Alanine Transaminase -- blood
- Antirheumatic Agents -- therapeutic use
- Arthritis, Rheumatoid -- drug therapy
- Aspartate Aminotransferases -- blood
- Cholesterol, HDL -- blood
- Cholesterol, LDL -- blood
- Creatinine -- blood
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Headache -- chemically induced
- Heterocyclic Compounds, 2-Ring -- therapeutic use
- Humans
- Janus Kinase 3 -- antagonists & inhibitors
- Male
- Methotrexate -- therapeutic use
- Middle Aged
- Treatment Outcome
- Valine -- analogs & derivatives
- Young Adult
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.